Thursday, 2 April 2020

Homeopathic Medicine Market Revenue, Opportunity, Forecast And Value Chain Analysis 2019

Market Insights
The market for homeopathy has expanded remarkably because of the increasing demand for natural remedies. Growing prevalence of chronic and lifestyle-related diseases such as obesity, diabetes, cancer, and fertility issues have led to a faster adoption of alternative medical treatments such as homeopathic medicine. However, the market is regulated by strict laws pertaining to the application of homeopathy in some developed nations like the U.K. and Germany. Meanwhile, many developing economies pose a high possibility for development attributing to the cultural propinquity for natural medication.
The WorldwideHomeopathic Medicine Market is expected to grow at a CAGR of 12.5% during the forecast period. The global homeopathic medicine market is expected to show sharp growth over the forecast period. Rising prevalence of chronic disease and increasing demand for medicines from natural sources and overall increase in the awareness about medicines and treatment options in homeopathy drive the market growth. Furthermore, homeopathy is gaining attention in many of the emerging market throughout the globe. Lack of awareness about homeopathy in developing countries may act as a barrier for the market growth.
Growing incidences of lifestyle-related and chronic diseases such as cancer, diabetes, obesity, and fertility problems have led to the increased adoption of alternative medical treatments such as homeopathic medicine, this driving market demand. The homeopathic medicine market is restrained by the implementation of strict regulations surrounding the use of homeopathy in certain developed economies such as Germany and the U.K. Meanwhile; emerging economies carry a high potential for growth due to the cultural affinity for natural medication in several fast emerging markets.
Regional Analysis
Led by the U.S, the Americas account for the largest share of the global market due to the high awareness regarding homeopathic medicine. Highly expensive healthcare often encourages patients to adopt homeopathic medicine. Moreover, the region is witnessing a rising occurrence in lifestyle-related diseases which further facilitate increased demand for homeopathic medicine.
Europe accounts for the second largest share due to the high number of homeopathic practitioners available in the region. U.K leads the regional market with the most significant share. The European region has widespread use of homeopathic medicine for day to day use in assisting the treatment of minor health problems.
In Asia Pacific, rising demand for alternative medicine such as homeopathy and Ayurveda, the prevalence of chronic diseases such as diabetes and obesity and increasing in the adoption of medicines from natural sources drive the market growth. Homeopathic Medicine Market Size in India is the largest for in Asia Pacific owing to its largest homeopathic infrastructure in the world and increasing in the number of homeopathic medical institutes and research centers.  Japanese Homoeopathic Medical Association is engaged in the academic research, promotion and international exchange of homoeopathy in Japan. Whereas, homeopathy is relatively unknown and moderately practiced in China.
Key Players
The competitive analysis of the market in MRFRs report records the strategies and market positions of leading market players such as Natural Health Supply, Boiron, HomeoLab USA, Hyland's Homeopathic, SBL, Nelson & Co. Ltd., and Hahnemann Laboratories Inc.
Latest Industry News
  • NHS funded homeopathic treatments have been cut off with exceptions to be considered on a case by case basis.
  • Indian homeopathy start-up Welcomecure has raised undisclosed investment from Bollywood Thier association with the brand is expected to increase demand.
Market Segmentation
The global homeopathic medicine market is segmented on the basis of type, indication, and end users.
On the basis of drugs, market is segmented into plants based, animal based and mineral based. Plant based is further segmented into Arnica montana, Bryonia alba, Cinchona officinalis, Pulsatilla nigricans, Rhus tox, Symphytum. Animal based is further segmented into Latrodectus mactans, Tarentula Hispania, Tarentula cubensis, Naja tripudians, Vipera, Sepia, and Cantharis. Mineral based is further segmented into Calcarea carbonica, Phosphorus, Calcarea phosphorica, Natrum muriaticuma and others. Other segments are Nosodes, Sarcodes and Imponderabilia.
On the basis of application, the market is segmented into skin & hair, reproductive health, lifestyle disorders, bones, joints, and muscles diseases, brain and nerves disorders, respiratory diseases, childhood diseases, hormonal disorders and others.
On the basis of end user, the market is divided into hospitals, homeopathic clinics, and others.

Posted by at No comments:

Carcinoid Syndrome Management Market Expected To Boost During 2019 To 2022

Market Scenario:
Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.
Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of global carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.
Segmentation:
The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented intochemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
Key players
  • Novartis International AG (Sandoz)
  • Pharmascience Inc.
  • Omega Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Ipsen Biopharmaceuticals, Inc.
  • Sirtex Medical Limited
  • BTG International Ltd.
  • Wockhardt Ltd.
  • Sun Pharmaceutical Industries Limited
Study Objectives:
  • To provide detail analysis of parent market and the changing market dynamics of the industry.
  • To provide detail analysis of the market structure along with estimated future growth forecast about various segments and sub-segments of the global carcinoid syndrome management market.
  • To provide in depth market segmentation and historical, current and projected market size in terms of value and volume with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future growth prospect.
  • To provide detailed analysis on recent industry trends and developments, strategies of key players and competitive landscape of the market.
  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place  in the global  Carcinoid Syndrome Management.
Regional Analysis
The Global Carcinoid Syndrome Management is segmented on the basis of regions, into North America, Europe, Asia-Pacific, and Middle East & Africa. America accounts for the largest market share of the Global Carcinoid Syndrome Management by region in 2016. High per capita healthcare expenditures followed by increasing awareness of the diseases and presence of the developed healthcare sector are the major drivers for the market growth during the forecast period. Followed by the North America, Europe holds the second largest market. Asia pacific is the fastest growing region. However, the Middle East and Africa region holds the least share of the global market, especially due to the presence of the poor economies within the Asia Pacific region. In the Middle East & African region, the Middle East holds the largest market share.
Posted by at No comments:

Anti-Viral Drugs Market Value Share, Supply Demand, Share And Value Chain 2019

Market Scenario:
The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.
The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug market growth.
The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.
However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period. 
Market Segmentation:
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market. 
Key Players
MRFR have enlisted some of the prominent companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 
Posted by at No comments:

Global Bioinformatics Market Production, Capacity, Revenue, Price, Gross Margin Analysis And Forecast 2019-2023

Market Scenario:
Bioinformatics is the use of information technology in the field of biotechnology for the purpose of data storage, data warehousing and analyzing the DNA sequences. In bioinformatics technology knowledge about various  branches is required which includes  biology, mathematics, computer science, laws of physics & chemistry along with it  most importantly sound knowledge about  information technology is required to analyze biotechnological data.
Globally the market for bioinformatics is growing steadily and has a bright future, this market expected to grow at the rate of about 19.8% till 2022 and this has started since 2016.
Study Objectives of Bioinformatics Market:
  • To provide detail analysis of the market structure along with forecast for the next 7 years about various segments and sub-segments of the global bioinformatics market.
  • To provide insights about factors affecting the market growth.
  • To analyze the market based on price analysis, supply chain analysis, Porters Five Force analysis etc.
  • To provide past and estimated future revenue of the market’s  segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future growth prospective.
  • To provide country level analysis of the market for segments by drug application, by technology, by sector and services and its sub-segments.
  • To provide overview about key players and their strategic profiling in the market; comprehensively analyzing their core competencies and drawing a competitive landscape of the market.
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Bioinformatics market.

Key Players for Bioinformatics Market:                                                        

Some of the key players in this market are: Agilent Technologies, Illumina, Inc., QIAGEN N. V, and Thermo Fisher Scientific Inc., Dassault Systèmes, QIAGEN and others.   
Segments:      
Bioinformatics market has been segmented on the basis of application which comprises of genomics, chemoinformatics, drug design, transcriptomics, molecular phylogenetics, proteomics, metabolomics, DNA sequences and others. On the basis of services and technology the market is segmented into data warehousing, sequence analysis, sequence manipulation and others. On the basis of sector the market is divided into medical bioinformatics, animal bioinformatics, agriculture bioinformatics and others.

Regional Analysis of Bioinformatics Market:                                                         
Globally Americas is the largest market for Bioinformatics. Where in countries like US and Canada play an important role in the growth of the market. Europe is expected to be the second-largest market which is expected to reach US$ XX million by the end of the forecasted period. Furthermore Asia pacific market is expected to be the fastest growing market for Bioinformatics.
Posted by at No comments:

Regenerative Medicine Market To Observe Strong Development By 2022

Regenerative Medicine Market information, By Material (Synthetic Materials, Genetically Engineered Materials, Pharmaceuticals), By Therapy (Stem Cell Biology, Cellular Therapy, Tissue Engineering), By Application (Cord Blood, Oncology, Urology, Orthopedics, Neurology, Dermatology) - Forecast till 2022      
Market Synopsis of Regenerative Medicine Market:

Market Scenario:

The Global Regenerative Medicine Market is growing steadily. Factors that influence the regenerative medicine market are increasing advancement in healthcare technology, increasing advance technology in regenerative medicine market, increasing prevalence of chronic diseases, increasing growth in stem cell technology and others. Globally the market for regenerative medicine is expected to grow at the rate of about 25.4% from 2016 to 2022.

Study objectives of the Market:

  • Providing detail analysis of the market structure along with forecast for the next 7 years of various segments and sub-segments of the Regenerative medicine market.
  • Giving insights about factors affecting the market growth.
  • Analyzing the market based on various factors- price analysis, supply chain analysis, Porters Five Force analysis etc.
  • Giving the past revenue and predicted future revenue of the market segments and sub-segments with respect to the main market and various markets globally.
  • Giving regional level analysis of the market with respect to the current market size and future prospective.
  • Giving regional level analysis of the market with respect to segments, application, material and market’s sub-segments.
  • Providing an overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive structure of the market.
  • Tracking and analyzing competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments in the global Regenerative medicine market.
Key Players for Regenerative Medicine Market:                                          
Some of the key players in this market are: Cook Biotech, Osiris Therapeutics, Organogenesis,  Stryker and RTI surgical, Baxter International, Inc., LifeSciences, Advanced Cell Technology, CryoLife, Sanofi, BioMimetic Therapeutics, StemCellsInc, Medtronic, LifeCell Kinetic Concepts and others. 
Segments:     
Global regenerative medicine market has been segmented on the basis of material which comprises synthetic materials, genetically engineered materials, pharmaceuticals, biologically derived materials and others. On the basis of therapy the market is segmented into stem cell biology, cellular therapy, tissue engineering and others. Furthermore on the basis of application the market is segmented into cord blood, oncology, urology, orthopedics, neurology, dermatology, cardiovascular, orthopedic and others.
Regional Analysis of Regenerative Medicine Market:                                           
Globally North America is the largest market for regenerative medicine market. North America holds the largest market share of more than 44% of the global regenerative medicine market and is expected to grow at a CAGR of 22.3%. Europe is the second-largest market for Regenerative medicine which is expected to grow at a CAGR of 22.5%. Asia pacific region is expected to be fastest growing region in regenerative medicine market.  
Posted by at No comments:

Stroke Disorder and Treatment Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2022

Heart problems and brain problems are considered among most dangerous medical problems, and their treatments are considered to be most expensive. Heart strokes and brain strokes can strike any moment and can be fatal. Hence, the market offering treatment for it is always lucrative. Globally it is increasing rapidly. The major factor that drives the growth of this market is the increasing high blood pressure patients. Due to increasing alcoholism and patients with diabetes, cardiovascular diseases are increasing the growth of this disorder and the market offering its treatment.
Market Research Future (MRFR) has published a research report about the global stroke disorder and treatment market that estimates huge aggrandizement in this market between 2016 and 2022. This report provides a detailed analysis of the market structure along with a forecast for the next seven years. It analyzes the market on the basis of various factors including porters five force analysis, price analysis, and supply chain analysis. Providing insights about the current market size and future prospects, this report features expert opinions. Profiling the key players in the market, this report covers competitive developments such as joint ventures, mergers and acquisitions, new product developments, strategic alliances, and research and developments in the global market.
The global stroke disorder and treatment market has been segmented into medicines, treatment, types, and lastly region. On the basis of medicines, this market has been segmented into anticoagulants, anti-hypertensive, and antiplatelet. Anticoagulants, also called blood thinners, are chemical substances that prevent or reduce coagulation of blood, prolonging the clotting time. Apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa), enoxaparin (Lovenox), fondaparinux (Arixtra), heparin, rivaroxaban (Xarelto), and warfarin (Coumadin) are some examples of anticoagulants. Antiplatelet is a member of a class of pharmaceutical drugs that decrease platelet aggregation and inhibit thrombus formation. They are more effective in the arterial circulation compared anticoagulants. Examples of antiplatelet include clopidogrel (Plavix), dipyridamole/aspirin (Aggrenox), eptifibatide (Integrilin), prasugrel (Effient), ticagrelor (Brilinta), and ticlodipine (Ticlid). Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure). Examples of antihypertensives include benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec), lisinopril (Zestril and Prinivil), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), and trandolapril (Mavik).  
Treatment-based segmentation of the market covers tissue plasminogen activator (TPA) and endovascular procedures. TPA is an enzyme involved in the breakdown of blood clots and dissolves them. The endovascular procedure is surgery. Being innovative, it is a less invasive procedure, popularly used for treating problems affecting the blood vessels, such as an aneurysm, which is a swelling or “ballooning” of the blood vessel. By types, the market has been segmented into hemorrhagic strokes and ischemic stroke. The weakened blood vessel leakage is called a hemorrhagic stroke. Its two categories are aneurysms and arteriovenous malformations. Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain.
The regional segmentation of global stroke disorder and treatment market cover North America, Europe, and the Asia Pacific. The key players of this market are primarily based in these continents. In other parts of the world, the market for stroke disorder and treatment is limited due to less advanced medical facilities, little investment in health care, lack of awareness about stroke disorder, and poor infrastructure. In North America and Europe, investments in research and development (R & D) and advanced medical facilities boost this market. According to this report, the market in North America is expected to rise and earn maximum revenue by the end of the forecast period. Europe is the second largest market. The Asia Pacific is expected to be the fastest growing market for stroke disorder and treatment because some countries in this region do have advanced medical facilities.
Key Players
The key players of global stroke disorder and treatment market include AstraZeneca {United Kingdom (UK)}, Bayer Pharma AG (Germany), Daiichi Sankyo (Japan), Novartis AG (Switzerland), and Pfizer {United States of America (US)}.
Posted by at No comments:

Ventilator-Associated Pneumonia Market Trends, Analysis And Review During 2019 To 2025

Global Ventilator-Associated Pneumonia Market Research Report: Information by Diagnosis (Clinical, Radiological, Microbiological, and Others), End User (Hospitals & Clinics, Research & Academic Institutes, Ambulatory Care Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025
Market Scenario
According to CDC in 2013, there were 2.8 million traumatic brain injury visits to emergency department and hospitals. The emergency department visits of brain injury patients increased by 47% from 2007. Thus, increasing incidence of TBI drives the growth of the market. Furthermore, increasing geriatric population is likely to fuel the market to grow.  According to the U.S. Census Bureau in 2015, 47.8 million people were 65 years or older, and in 2060, 98.2 million are expected to be 65 years or older.  Such increasing trend in the geriatric population provides favorable backgrounds for the market to grow.
Ventilator-associated pneumonia is a type of lung infection caused to patients who are on ventilators. Ventilator-associated pneumonia is caused mainly due to lung disease, neurologic disease, and trauma to critically ill persons. Diagnosing VAP requires aggressive surveillance combined with the radiographic examination, bedside examination, and microbiologic examinations of respiratory secretions. Growing Intensive Care Unit Admissions due to rising prevalence of respiratory diseases, rising number of ICU beds and high incidence of traumatic injuries provides favorable backgrounds for the market to grow.
However, factors such as expensive diagnostic tests, high ventilator charges, inappropriate reimbursement scenario, risks associated with ventilators are expected to restrict the market growth during the forecast period.
Key players
Some of the key players contributing in the global Ventilator-associated pneumonia market are Merck & Co., Inc. (U.S.), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria) and other.
Segmentation
The global Ventilator-associated pneumonia market is segmented on the basis of diagnosis, mode of treatment, and end-user. The Ventilator-associated pneumonia market, by diagnosis categorized into Clinical Examination, Radiological Examination, Microbiological Analysis and others. Microbiological Analysis is further sub-segmented into Blood and pleural fluid cultures, Nonquantitative or semi-quantitative airway sampling and Quantitative cultures of airway specimens. Mode of treatment segment is segmented into Homecare, Hospital care, and others. On the basis of end-user, the market is segmented into Hospitals & Clinics, Research centers, Ambulatory Care Centers and Emergency Medical Services (EMS).      
Regional Market Summary
The Ventilator-associated pneumonia market is dominated by North America owing to the rising geriatric population within the region. The U.S. Census Bureau projected that in 2060, 19.7 million would be of age 85 or older. This influences the growth of this market in this region.
Asia Pacific was projected to be the fastest growing region for the global Ventilator-associated pneumonia market in 2017. The rising geriatric population, increasing healthcare expenditure and growing respiratory disorders in Asia is expected to drive market growth in this region. According to The Asian Development Bank (ADB), the geriatric population in Asia is estimated to reach 923 million by 2050. Thus, this provides favorable backgrounds for the Ventilator-associated pneumonia market to grow.
It is estimated that Europe stood second in the global Ventilator-associated pneumonia market owing to increasing prevalence of lung diseases. According to European respiratory society, more than 50% of deaths are due to lung diseases. Thus, increasing prevalence of lung diseases in this region influences the growth of this market in this region.
The Middle East and Africa holds the least share in the global Ventilator-associated pneumonia market due to the presence of stringent government policies, poor economies, under-developed healthcare infrastructure and low penetration of healthcare services, especially within the African region.
Posted by at No comments:
Subscribe to: Posts (Atom)